Sanofi agrees to settle thousands of Zantac Zantac cancer claims

2024-04-05

专利侵权

Sanofi confirmed to FirstWord on Friday that it reached a deal in principle to settle approximately 4000 personal injury lawsuits accusing the company of selling the now-discontinued heartburn medicine Zantac (ranitidine) without warning patients that it could potentially cause cancer.

The settlement, which marks the first major resolution of cases related to the product, will apply to litigation pending in courts in US states other than Delaware.

"Sanofi has vigorously defended the Zantac litigation since the outset and will continue to do so," said a Sanofi spokesperson. "Consistent with the federal court's ruling that plaintiffs had insufficient evidence that ranitidine can cause plaintiffs' alleged cancers, the medical, scientific, and regulatory communities have extensively evaluated and have found the allegations of the plaintiffs that Zantac causes cancer to be without merit."

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构